相关实验视频
Updated: Sep 17, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.5K
为功能进行校正对血 fosforylated tau 性能对阿尔茨海默病的功效的影响
Kenichiro Sato1,2, Yoshiki Niimi2,3, Ryoko Ihara4
1Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Journal of Alzheimer's disease : JAD
|June 30, 2025
概括
在阿尔茨海默病 (AD) 测试中,针对血基生物标志物 (BBM) 的功能校正显示敏感性降低和特异性增加. 这种调整对于在不同患者群体中准确解释AD病理学至关重要.
科学领域:
- 神经学 神经学
- 生物标志物 生物标志物
- 老年学是一门学科.
背景情况:
- 基于血液的生物标志物 (BBM),如化的 (pTau) 提供了不那么侵入性的阿尔茨海默病 (AD) 检测.
- 慢性病中血pTau升高需要仔细解释,因为功能校正会影响测试性能.
研究的目的:
- 量化功能正对BBM检测AD病理的表现的影响.
- 评估功能调整如何影响pTau测试的灵敏度,特异性和整体准确性.
主要方法:
- 来自日本和ADNI队伍的血pTau181和pTau217水平的分析,包括患有功能障碍 (eGFR <60) 的参与者.
- 对粉样蛋白PET阳性的预测模型的比较,包括和没有功能纠正.
主要成果:
- 脏纠正降低了0.06-0.07的灵敏度,增加了0.04-0.10.10的特异性.
- 在预测值和平衡精度中观察到微小的增加 (<0.02).
- 校正效应更为明显,功能障碍的患病率更高,特别是对于敏感性和特异性.
结论:
- 功能校正改变了BBM测试的性能,降低了灵敏度和增加了特异性.
- 总体预测的准确性没有受到损害,但解释必须考虑人口特征.
- 强调在现实环境中解释BBM结果时考虑患者功能的重要性.
相关概念视频
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678
Renal Failure: Dose Adjustments
166
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
166
Factors Affecting Renal Clearance: Renal Impairment
165
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
165
Phosphorylation
51.2K
The addition or removal of phosphate groups from proteins is the most common chemical modification that regulates cellular processes. These modifications can affect the structure, activity, stability, and localization of proteins within cells as well as their interactions with other proteins.
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
51.2K

